Articles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Current Editions
Search Archives
BCIQ
Company Profiles
Target Profiles
Product Profiles
Conferences
China Healthcare Summit
Bio€quity Europe
White Papers
Free Trial
/
Subscribe
Sign In
more_vert
Biocentury
Company Profiles
Target Profiles
Product Profiles
Free Trial Information
Export Pdf
Pipeline
Deals
Financings
Articles
BioCentury
|
Jan 22, 2021
Product Development
Slaoui on Warp Speed’s successes, limitations and lessons
...of doses, getting them into people’s arms, is another story. Why has it been so
bad
...
Read More
BioCentury
|
Jan 20, 2021
Politics, Policy & Law
Exit interview: Hahn departs after tumultuous tenure, advocating greater independence for FDA
...reckless, incompetent and uncaring President, some really
bad
...
Read More
BioCentury
|
Jan 12, 2021
Product Development
Lilly’s amyloid therapy not a big step forward from Biogen’s
...the idea that soluble oligomers are the
bad
...
Read More
BioCentury
|
Jan 9, 2021
Product Development
Possible factors behind Sarepta’s DMD miss
...but instead, “appears to relate to improbable
bad
...
Read More
BioCentury
|
Jan 1, 2021
Deals
The good, the bad and the COVID: BioCentury’s playlist for pandemic times
Saying goodbye to a grueling year, BioCentury editors have furrowed among the disasters to pick out some of the positives from 2020, and call out some of the worst of the pandemic’s collateral damage....
Read More
BioCentury
|
Dec 31, 2020
Product Development
Stoffels on how J&J designed its COVID-19 vaccine for maximum impact: a BioCentury audio interview
...next time, and avoid this type of suffering for the world? Because it's a very
bad
...
Read More
BioCentury
|
Dec 30, 2020
Product Development
2020’s silver linings, New Year’s hopes: a BioCentury podcast
...Jeff Cranmer: So let's get to the
bad
...
...with how much regulation is good or
bad
...
...I don't know that it was as
bad
...
Read More
BioCentury
|
Dec 18, 2020
Product Development
2021 Predictions: a BioCentury survey
...targets,” wrote one respondent. “At least one
bad
...
Read More
BioCentury
|
Dec 10, 2020
Deals
Late in a year of cancer deals, Gilead spends $1B+ to add an antiviral for HDV
...included Maxwell Biotech Venture Fund and High-Tech Gründerfonds. Founded in 2011, the company is based in
Bad
...
Read More
BioCentury
|
Dec 8, 2020
Product Development
ASH Monday, Biden’s picks & vaccine conundrums: a BioCentury podcast
...they take them just by chance some
bad
...
Read More
Items per page:
10
1 - 10 of 1099
Previous page
Next page